证券代码：688050 证券简称：爱博医疗 公告编号：2025-018 爱博诺德（北京）医疗科技股份有限公司 第二届监事会第十五次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 爱博诺德（北京）医疗科技股份有限公司（以下简称"公司"）第二届监事 会第十五次会议通知及相关材料于 2025 年 4 月 11 日以电子邮件的方式发出。会 议于 2025 年 4 月 21 日在公司会议室以现场与通讯相结合方式召开，本次会议由 监事会主席王丹璇女士召集并主持，应出席的监事 3 人，实际出席的监事 3 人。 本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法律、法规、 规章、规范性文件和《公司章程》等有关规定，会议形成的决议合法、有效。经 与会监事认真讨论，审议通过如下事项： 一、审议并通过《关于<2024 年度监事会工作报告>的议案》 经与会监事认真审议，2024 年度，公司监事会按照相关法律法规要求，从切 实维护公司利益和广大中小股东权益出发，认真履行了自身职责，对 2024 年度公 司的各方面情况进行了 ...

一、审议并通过《关于<2024 年度总经理工作报告>的议案》 经与会董事认真审议，报告期内，公司总经理围绕高质量发展，在企业治理、 研发创新、产品质量、客户服务等方面持续发力，同时，积极回应利益相关方对 公司的关注与期望，履行上市公司的责任和义务。董事会同意通过其工作报告。 表决结果：同意 9 票，反对 0 票，弃权 0 票。 二、审议并通过《关于<2024 年度董事会工作报告>的议案》 证券代码：688050 证券简称：爱博医疗 公告编号：2025-017 爱博诺德（北京）医疗科技股份有限公司 第二届董事会第十八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 爱博诺德（北京）医疗科技股份有限公司（以下简称"公司"）第二届董事 会第十八次会议通知及相关材料于 2025 年 4 月 11 日以电子邮件方式发出。会议 于 2025 年 4 月 21 日在公司会议室以现场与通讯相结合方式召开，本次会议由董 事长解江冰先生召集并主持，应出席参加表决的董事 9 人，实际出席参加表决的 董事 9 人，全体监事和高级管理 ...

证券代码：688050 证券简称：爱博医疗 公告编号：2025-023 爱博诺德（北京）医疗科技股份有限公司 关于延迟审议 2024 年度利润分配方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 爱博诺德（北京）医疗科技股份有限公司（以下简称"公司"）拟延迟审 议 2024 年度利润分配方案。 ● 公司拟延迟审议 2024 年度利润分配方案的原因：根据中国证监会《证券 发行与承销管理办法》的相关规定，为确保上市公司证券发行的规范性与公平性， 上市公司发行证券与权益分派方案不可同时进行。待本次发行完成后，公司将尽 快按照法律法规、监管部门的要求与《公司章程》等规定审议、实施利润分配事 项。 ● 公司第二届董事会第十八次会议和第二届监事会第十五次会议审议通过了 《关于延迟审议 2024 年度利润分配方案的议案》，该议案尚需提交股东大会审议。 一、拟延迟审议的 2024 年度利润分配方案的主要内容 经信永中和会计师事务所（特殊普通合伙）审计，截至 2024 年 12 月 31 日， 母公司期末可供分 ...

Financial Performance - The company achieved total operating revenue of RMB 1,410,022,458.11 in 2024, representing a year-on-year growth of 48.24%[24]. - Net profit attributable to shareholders reached RMB 388,402,949.75, an increase of 27.77% compared to the previous year[24]. - The company's cash flow from operating activities amounted to RMB 347,754,061.87, reflecting a 63.56% increase year-on-year[24]. - Basic earnings per share for 2024 were RMB 2.05, up 27.33% from RMB 1.61 in 2023[25]. - The company's total assets at the end of 2024 were RMB 3,496,968,135.88, a 14.21% increase from the previous year[24]. - The company's net profit attributable to shareholders reached ¥388,402,949.75, representing a year-on-year increase of 27.77%[26]. - The total revenue for 2024 reached ¥1,410,022,458.11, representing a year-on-year growth of 48.24% compared to ¥951,177,100.86 in 2023[35]. - The cash received from sales increased by 42.78% compared to the same period last year, slightly lower than the revenue growth rate[26]. Research and Development - The company's R&D investment as a percentage of operating revenue was 11.33%, a decrease of 2.58 percentage points from the previous year[25]. - The company invested ¥159,819,056.53 in R&D during the reporting period, a 20.80% increase, accounting for 11.33% of total revenue[38]. - The company filed for 51 new patents during the reporting period, with 49 patents granted, bringing the total to 498 applications and 337 granted patents[69]. - The company achieved a total R&D investment of ¥159,819,056.53, representing a 20.80% increase compared to the previous year[71]. - The number of R&D personnel increased to 293, representing 12.77% of the total workforce, up from 10.13% in the previous period[78]. - The company is focusing on expanding its product line with new medical-grade hyaluronic acid fillers, with projected revenue of $20 million for one of the products[75]. - The company is actively pursuing clinical trials for several new products, including a new injection for craniofacial applications, with expected revenue of $20 million[76]. Product Development and Innovation - The company is focused on developing innovative products, including aspheric trifocal astigmatism-correcting intraocular lenses and silicone hydrogel contact lenses[34]. - The company has established itself as a leader in the Chinese ophthalmic medical device industry, being the only manufacturer to successfully develop multifocal intraocular lenses independently[54]. - The company is actively expanding its product layout in myopia prevention, introducing various new products to adapt to market competition[36]. - The company is exploring advanced optical designs, including extended depth of focus (EDoF) technology, to improve visual quality for patients[59]. - The company is focusing on the development of preloaded, minimally invasive, and personalized cataract surgery solutions to meet clinical needs[59]. - The company has developed hydrophobic acrylic materials that effectively reduce the incidence of posterior capsule opacification (PCO) and provide reliable support for implanted intraocular lenses[60]. - The company’s corneal reshaping lenses utilize a fluorosilicone acrylate polymer material with high oxygen permeability (125 Dk), ensuring high comfort and safety for patients[60]. Market Expansion and Strategy - The company is focused on expanding its market presence and developing new products and technologies, although specific figures are not provided in the current report[9]. - The company is expanding its market presence and accelerating domestic substitution and international expansion strategies[34]. - The company has established a strong presence in international markets, exporting products to over 30 countries across Europe, Asia, Africa, and the Americas[86]. - The company plans to enhance its market penetration in over 6,000 hospitals and optical centers across China, focusing on artificial lenses and orthokeratology lenses[196]. - The company aims to prioritize market opportunities in Europe and Southeast Asia for expansion[200]. - The company intends to collaborate with leading international ophthalmology and vision care companies to introduce high-end ophthalmic medical devices to the Chinese market[200]. Risks and Challenges - The company has detailed various risk factors in its operations, which are elaborated in the management discussion and analysis section[6]. - The company faces risks related to product upgrades and new product development, which may impact its market share and profitability[88]. - The company faces risks related to the inability to comply with agreements and regulations, which may compromise the integrity of trial data[89]. - The company is at risk of talent loss and technology leakage, which could disrupt business and delay expansion strategies[90]. - The company may encounter challenges in fulfilling contractual obligations, leading to potential liabilities and reputational damage[113]. - The company faces intense competition in the ophthalmic surgery market from large multinational manufacturers with multiple product lines[126]. - The company must comply with various regulations to maintain necessary licenses and approvals, which can be time-consuming and costly[129]. Corporate Governance and Compliance - The company has confirmed that there are no non-operational fund occupations by controlling shareholders or related parties[10]. - The company has not disclosed any special arrangements for corporate governance, indicating standard practices are in place[10]. - The company received a standard unqualified audit report from its accounting firm, ensuring the accuracy of its financial statements[7]. - The company has confirmed that all board members are present and have ensured the integrity of the annual report[7].

Financial Performance - The company's operating revenue for Q1 2025 was ¥357,183,134.15, representing a 15.07% increase compared to ¥310,403,646.88 in the same period last year[4] - Net profit attributable to shareholders decreased by 10.05% to ¥92,558,116.80 from ¥102,903,404.36 year-on-year[4] - Total operating revenue for Q1 2025 reached ¥357,183,134.15, an increase of 15.1% compared to ¥310,403,646.88 in Q1 2024[20] - Net profit for Q1 2025 was ¥89,813,380.76, a decrease of 8.3% from ¥98,465,202.47 in Q1 2024[21] - Basic earnings per share for Q1 2025 were ¥0.49, down from ¥0.54 in Q1 2024[22] Cash Flow - The net cash flow from operating activities increased by 39.93% to ¥75,500,313.06, primarily due to increased collections from the contact lens business[7] - Cash generated from operating activities in Q1 2025 was ¥359,174,461.93, compared to ¥283,185,429.75 in Q1 2024, reflecting a growth of 27%[24] - The net cash flow from operating activities was $75,500,313.06, an increase from $53,954,775.47 in the previous period, reflecting a growth of approximately 39.7%[25] - Cash inflow from investment activities totaled $204,683,130.17, significantly up from $20,129,743.84, indicating a growth of about 917.5%[25] - The net cash flow from investment activities was -$103,540,404.89, an improvement compared to -$185,226,525.61 in the prior period, showing a reduction in losses by approximately 44.1%[25] - Cash inflow from financing activities was $30,050,625.12, down from $92,659,147.60, representing a decline of about 67.6%[26] - The net cash flow from financing activities was $6,425,798.07, a recovery from a negative cash flow of -$37,507,754.35 in the previous period[26] - The total cash and cash equivalents at the end of the period were $342,330,078.55, down from $367,878,406.19, reflecting a decrease of approximately 6.9%[26] - The company received $197,899,999.95 from investment recoveries, a substantial increase from $20,000,000.00 previously, marking a growth of about 889.5%[25] - Payments for the purchase of fixed assets and other long-term assets were $56,597,243.51, a decrease from $126,246,790.60, indicating a reduction of approximately 55.2%[25] - The company paid $35,641,250.89 in taxes, which is an increase from $18,453,212.98, reflecting a growth of about 93.3%[25] - The cash outflow for financing activities totaled $23,624,827.05, a significant decrease from $130,166,901.95, indicating a reduction of approximately 81.8%[26] Research and Development - Research and development expenses totaled ¥40,002,099.32, a 34.12% increase from ¥29,826,271.11 in the previous year, reflecting higher investment in high-end crystals and contact lenses[4][7] - The proportion of R&D expenses to operating revenue rose to 11.20%, up from 9.61% year-on-year, an increase of 1.59 percentage points[5] - Research and development expenses for Q1 2025 amounted to ¥26,197,363.60, an increase of 24.5% from ¥21,009,110.98 in Q1 2024[21] - The company plans to increase investment in research and development and enhance market promotion efforts to navigate challenges and uncertainties in the domestic and international landscape[13] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,536,075,923.73, a 1.12% increase from ¥3,496,968,135.88 at the end of the previous year[5] - The total non-current assets amounted to RMB 1,454,060,342.49 as of March 31, 2025, showing stability in long-term investments[16] - Total liabilities increased to ¥870,103,044.26 from ¥862,711,621.16, indicating a slight rise of 1.4%[18] - The company's total equity rose to ¥2,665,972,879.47, up from ¥2,634,256,514.72, reflecting a growth of 1.2%[18] - Deferred income tax assets increased to ¥80,353,423.64 from ¥72,887,109.65, marking an increase of 10.1%[17] Market Conditions and Competition - The company anticipates a slowdown in revenue growth for the first quarter of 2025 due to the implementation of national procurement policies affecting artificial lenses, leading to reduced surgical volumes and lower prices[13] - The company is facing intensified competition in the myopia prevention market, which has resulted in a slight decrease in the factory price of orthokeratology lenses, impacting performance growth[13] - The company's contact lens business is still in the cultivation stage, contributing minimally to profits but with significant potential for future growth[13] - The company has a consistent strategy to achieve its annual performance targets despite market challenges[13] Shareholder Information - The company had a total of 9,729 common shareholders at the end of the reporting period[9] - The top shareholder, Jiang Bing, holds 12.92% of the shares, amounting to 24,490,410 shares[9] - The top ten shareholders include significant holdings from individuals and entities, with the largest shareholder holding 24,490,410 shares[12]

爱博诺德（北京）医疗科技股份有限公司 2024 年度 内部控制审计报告 索引 内部控制审计报告 页码 1-2 联系电话: 信永中和会计师事务所 | 北京市东城区朝阳门北大街 telephone: +86 (010) 6554 2288 8 号富华大厦 A 座 9 层 ShineW 100027. P.R. China certified public accountants 9/F, Block A, Fu Hua Mansion No.8, Chaoyangmen Beidajie Dongcheng District, Beijing 内部控制审计报告 XYZH2025BJAA12B0096 爱博诺德(北京)医疗科技股份有限公司 爱博诺德(北京)医疗科技股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我们审计 了爱博诺德（北京）医疗科技股份有限公司（以下简称爱博医疗公司）2024 年 12 月 31 日财务报告内部控制的有效性。 一、企业对内部控制的责任 86 /010) 6554 7100 86 (010) 6554 7190 按照《企业内部控制基本规范》 、《企 ...

爱博诺德（北京）医疗科技股份有限公司 2024 年度 审计报告 | 索引 | | 页码 | | --- | --- | --- | | 审计报告 | | 1-4 | | 公司财务报表 | | | | 一 合并资产负债表 | | 1-2 | | 母公司资产负债表 | | 3-4 | | - | 合并利润表 | 5 | | 母公司利润表 | | 6 | | 合并现金流量表 | | 7 | | 母公司现金流量表 | | 8 | | 合并股东权益变动表 | | 9-10 | | 母公司股东权益变动表 | | 11-12 | | 财务报表附注 | | 13-104 | 联系电话: 信永中和会计师事务所| 北京市东城区朝阳门北大街 8 号富华大厦 A 座 9 层 ShineW certified public accountants 9/F. Block A. Fu Hua Mansion No.8. Chaovangmen Beidaiie Donachena District. Beijing 100027 P R China 6 /010) 6554 7190 窗计报告 XYZH/2025BJAA12B0097 爱 ...

爱博诺德（北京）医疗科技股份有限公司 非经营性资金占用及其他关联资金往来的 专项说明 | 索引 | 页码 | | --- | --- | | 专项说明 | 1-2 | | 非经营性资金占用及其他关联资金往来情况汇总表 | 1-1 | t and the state | | 4 6 3 | | | | --- | --- | --- | --- | | | | 8 号富华大厦 A 座 9 层 | telephone: +86 (010) 6554 2288 | | Dhinelling | I ShineWing | 9/F, Block A, Fu Hua Mansion, No.8, Chaoyangmen Beidajie, | | | | | Dongcheng District, Beijing, 传真: | +86 (010) 6554 7190 | | | certified public accountants 100027, P.R.China | | facsimile: +86 (010) 6554 7190 | 关于爱博诺德（北京）医疗科技股份有限公司 2024 年度非经营性资金占用及其 ...

中国银河证券股份有限公司 关于爱博诺德（北京）医疗科技股份有限公司 2024 年度募集资金存放与使用情况的核查意见 中国银河证券股份有限公司（以下简称"银河证券"或"保荐机构"）作为 爱博诺德（北京）医疗科技股份有限公司（以下简称"爱博医疗"或"公司"） 持续督导的保荐机构，根据《上市公司监管指引第 2 号——上市公司募集资金管 理和使用的监管要求》《上海证券交易所科创板股票上市规则》《科创板上市公 司持续监管办法（试行）》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等有关规定，就爱博医疗 2024 年度募集资金存放与使用情况 进行了核查，具体情况如下： 一、募集资金基本情况 （一）募集资金金额及到位时间 经中国证券监督管理委员会证监许可[2020]1306 号文《关于同意爱博诺德 （北京）医疗科技股份有限公司首次公开发行股票注册的批复》同意，爱博医疗 向社会公开发行人民币普通股（A 股）2,629 万股，每股发行价格为 33.55 元，募 集资金总额 882,029,500.00 元，扣除与发行有关的费用人民币 78,040,363.48 元， 实际可使用募集资金人民币 803,989 ...

爱博诺德（北京）医疗科技股份有限公司 2024 年度 募集资金存放与使用情况鉴证报告 | 蒙引 | 页码 | | --- | --- | | 鉴证报告 | 1-2 | | 2024 年度募集资金存放与使用情况的专项报告 | 1-10 | a | 信永中和 | | --- | | ShineWing | 联系电话: +86 (010) 6554 2288 信永中和会计师事务所| 北京市东城区朝阳门北大街 telephone: +86 (010) 6554 2288 8 号富华大厦 A 座 9 层 ShimeW 9/F, Block A, Fu Hua Mansion, No.8, Chaoyangmen Beidajie, Dongcheng District, Beijing, 100027, P.R.China 86 /010) 6554 7190 86 (010) 6554 7190 我们对后附的爱博诺德(北京)医疗科技股份有限公司(以下简称爱博医疗公司)关 于募集资金 2024 年度存放与使用情况的专项报告(以下简称募集资金年度存放与使用 情况专项报告)执行了鉴证工作。 爱博医疗公司管理层的责任是按照上 ...